Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Large Increase in Short Interest

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 3,840,000 shares, a growth of 8.2% from the December 31st total of 3,550,000 shares. Based on an average daily volume of 463,300 shares, the short-interest ratio is currently 8.3 days.

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ:ALDX traded down $0.05 during trading on Monday, hitting $5.19. The company’s stock had a trading volume of 100,931 shares, compared to its average volume of 329,520. Aldeyra Therapeutics has a 12 month low of $2.71 and a 12 month high of $6.55. The company has a 50-day moving average of $5.01 and a 200-day moving average of $5.08. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). On average, sell-side analysts anticipate that Aldeyra Therapeutics will post -0.92 earnings per share for the current year.

Institutional Trading of Aldeyra Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. American Century Companies Inc. grew its stake in Aldeyra Therapeutics by 216.7% in the second quarter. American Century Companies Inc. now owns 53,388 shares of the biotechnology company’s stock valued at $177,000 after purchasing an additional 36,528 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Aldeyra Therapeutics by 14.4% in the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 2,729 shares during the last quarter. SG Americas Securities LLC boosted its position in Aldeyra Therapeutics by 71.8% in the third quarter. SG Americas Securities LLC now owns 19,543 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 8,165 shares during the last quarter. International Assets Investment Management LLC lifted its holdings in Aldeyra Therapeutics by 397.0% in the third quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock valued at $15,480,000 after acquiring an additional 229,487 shares during the period. Finally, US Bancorp DE acquired a new position in Aldeyra Therapeutics in the third quarter valued at approximately $30,000. 59.71% of the stock is currently owned by institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.